RATIO-LISINOPRIL Z TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

LISINOPRIL

から入手可能:

RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED

ATCコード:

C09AA03

INN（国際名）:

LISINOPRIL

投薬量:

5MG

医薬品形態:

TABLET

構図:

LISINOPRIL 5MG

投与経路:

ORAL

パッケージ内のユニット:

100/500

処方タイプ:

Prescription

治療領域:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

製品概要:

Active ingredient group (AIG) number: 0121550003; AHFS:

認証ステータス:

CANCELLED POST MARKET

承認日:

2014-09-19

製品の特徴

_ _
_ratio-LISINOPRIL Z 5 mg, 10 mg and 20 mg Tablets _
_Page 1 of 39 _
PRODUCT MONOGRAPH
RATIO-LISINOPRIL Z
Lisinopril
Tablets 5 mg, 10 mg and 20 mg
USP
Angiotensin Converting Enzyme Inhibitor
ratiopharm inc.
Canada J7J 1P3
DATE OF PREPARATION: SEPTEMBER 20, 2007
CONTROL NUMBER: 110419
_ _
_ratio-LISINOPRIL Z 5 mg, 10 mg and 20 mg Tablets _
_Page 2 of 39 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL
USE.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
……………………………………………………..4
ADVERSE
REACTIONS.................................................................................................
10
DRUG INTERACTIONS
.................................................................................................
15
DOSAGE AND
ADMINISTRATION.............................................................................
16
SYMPTOMS AND TREATMENT OF OVERDOSAGE
............................................... 19
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 19
STORAGE AND
STABILITY.........................................................................................
22
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 22
PART II: SCIENTIFIC INFORMATION
..............................................................................
23
PHARMACEUTICAL
INFORMATION.........................................................................
23
CLINICAL
TRIALS.........................................................................................................
24
DETAILED
PHARMACOLOGY...............................................................